The Food and Drug Administration(FDA) of America recently approved the clinical trial of a glycoconjugate Group B meningitis(GBM) vaccine based on the chemically modified GBM capsular polysaccharied.

• FDA批准了一种新型糖蛋白缀合体作为乙型脑膜炎疫苗进入临床实验。